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Letter to the Editor
DIGOXIN DOES NOT PREVENT DAUNORUBICIN OR ADRIAMYCIN
FROM BINDING TO RAT HEART MUSCLE
Daunorubicin and adriamycin are anthra-
cycline drugs used in the chemotherapy of
acute myelogenous leukaemia and other
cancers (Crowther et al., 1973; Staquet et al.,
1975). Their use is limited by their tendency
to induce cardiac failure (Middleman, Luce
and Frei, 1971; Malpas and Bodley Scott
1969), but there have been a number of
reports (Lefrak et al., 1973; Kimura, 1972) to
suggest that these cardiotoxic effects may be
attenuated by the prior administration of
digoxin. The mechanism of this reported
attenuation is unknown, but it has been pro-
posed (Fiorentino et al., 1974) that perhaps
the cardiac glycoside digoxin competes with
the anthracycline glycosides for the same
binding sites. We have examined this
possibility in the rat but have found no
evidence to suggest that prior treatment with
digoxin can prevent adriamycin and dauno-
rubicin binding to rat cardiac muscle.
We used adult male Wistar rats, each
weighing approximately 250 g. Sets of 4
rats were injected intravenously with up to
500 ,ug digoxin, or alternatively by 3 daily
injections of 500 ,ug digoxin. At various
times after injection the rats were injected
with various amounts of daunorubicin; up
to 20 mg per rat. At 0, 4, 8 and 24 h after
daunorubicin injection a rat was killed, its
heart removed, washed in ice-cold isotonic
saline, minced, homogenized in 5 ml ice-cold
saline and the bound daunorubicin and its
metabolites extracted according to the
method of Huffman, Benjamin and Bachur
(1973). This method involves extraction
with an equal volume of 75% ethanol, 0 45
N HCI; removal of the precipitate by cen-
trifugation; concentrating the supernatant
under nitrogen, and chromatography of the
resulting solution on thin layer chromato-
graphy. In each case the entire extract
from one heart was spotted on Silica gel
60 (without fluorescent indicator) (Merck,
Darmstadt) and the chromatograms dev-
eloped using Solvent system I (CHC13
CH30H:CH3COOH;: 100:2: 2.5). No matter
what the ratio of injected digoxin to dauno-
rubicin, the pattern ofmetabolites is identical
to that extracted from a control rat receiving
only daunorubicin. This was confirmed
quantitatively by measuring the eluted spots
in a fluorimeter. A typical experiment is
shown in the Table.
Similar experiments have been performed
with drugs other than daunorubicin. We
have used adriamycin, propranolol (4 mg/
250 g rat), ICRF 159 (100 mg/rat), and digi-
toxin (500 pg/rat) instead of digoxin. Pro-
pranolol binds to beta-adrenergic receptors
and might therefore compete with daunoru-
bicin ifit were to bind to the beta receptors on
the heart. ICRF 159 has been reported to
afford some prophylactic protection against
TABLE. Fluorimeter Readings of Eluted Spots: excited at 474 nm, Fluorescence read at
550 nm on an Amico-Bowman Spectrophotofluorimeter. In this Experiment the Rats
received 200 ug Daunorubicin 3 h after receiving Saline or 500 ug Digoxin. Rats were
Killed 2 h Afterwards or 24 h Afterwards
Spot
Rat killed 2 h after
(launorubicin injection
Rat kille(d 24 h after
(launorubicin injection
Rf Colour No dligoxin 500 ,ug (ligoxin 1No (ligoxin
0 22 red 0-012 0 011 0 011
0-49 rect 0-021 0-018 0-019
*0.):3 red 0 056 0 057 0 059
0-71 yellow 0 007 0 009 0 009
Backgroutnd - 0-001 0-001 0-001
* This spot has the same Rf as the aglyconie ofdaunoutrbici,- in our experlimenits.
500 ,ug (ligoxin
0-013
0-019
0-0.8
0-008
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daunorubicin (Herman et al., 1972), and
digitoxin binds more avidly to receptors than
does digoxin. In no instance was a change
in the binding of daunorubicin and its
metabolites to cardiac muscle observed.
We therefore conclude that digoxin is
unlikely to have a prophylactic effect by
preventing the anthracycline cytotoxic drugs
from binding to cardiac muscle. If digoxin
has any effect in vivo, it is more likely that
the mechanism must rely on digoxin's
pharmacological activity on the cardiac
muscle and conducting tissues mediated
by its actions on the Na+/K+-activated
ATP-ase.
B. J. SMITH
D. KUNDU
Imperial Cancer Research Fund
Medical Oncology Unit
St Bartholomew's Hospital
London ECI.
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